Loading
Pamiparib is an oral parp inhibitor from BeiGene, in registered phase 3 trials for ovarian cancer.
Pamiparib is listed on ClinicalTrials.gov as an intervention in 1 registered phase 3 trial sponsored by BeiGene, in ovarian cancer. A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.
A PARP inhibitor: the name stem -parib marks a small molecule that blocks the PARP DNA-repair enzyme, lethal to tumour cells that already lack a second repair pathway.
1.Pamiparib slips into a pocket on its target.
Compare all products across the US, EU, UK, Japan, China and Australia →
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Pamiparib" OR ABSTRACT:"Pamiparib" OR TITLE:"BGB-290" OR ABSTRACT:"BGB-290") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Pamiparib, not a curated reading list.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.
Shares Ovarian cancer and the tags pipeline, registry-only.